107 related articles for article (PubMed ID: 15936551)
1. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery.
Chander S; Choo R; Danjoux C; Morton G; Pearse A; Deboer G; Szumacher E; Loblaw A; Cheung P; Woo T
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):719-24. PubMed ID: 15936551
[TBL] [Abstract][Full Text] [Related]
2. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Choo R; Chander S; Danjoux C; Morton G; Pearce A; Deboer G; Szumacher E; Loblaw A; Cheung P; Woo T
Can J Urol; 2005 Feb; 12(1):2547-52. PubMed ID: 15777493
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.
Pearce A; Choo R; Danjoux C; Morton G; Loblaw DA; Szumacher E; Cheung P; Deboer G; Chander S
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):78-83. PubMed ID: 16563657
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.
Choo R; Pearce A; Danjoux C; Morton G; Deboer G; Szumacher E; Loblaw A; Cheung P
Eur Urol; 2007 Dec; 52(6):1645-50. PubMed ID: 17140722
[TBL] [Abstract][Full Text] [Related]
5. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
[TBL] [Abstract][Full Text] [Related]
7. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer.
Cury FL; Souhami L; Rajan R; Tanguay S; Gagnon B; Duclos M; Shenouda G; Faria SL; David M; Freeman CR
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):842-8. PubMed ID: 16289909
[TBL] [Abstract][Full Text] [Related]
10. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
[TBL] [Abstract][Full Text] [Related]
11. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
12. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy.
Namiki S; Saito S; Tochigi T; Ioritani N; Terai A; Arai Y
Int J Urol; 2007 Mar; 14(3):186-91. PubMed ID: 17430252
[TBL] [Abstract][Full Text] [Related]
13. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial.
Black PC; Basen-Engquist K; Wang X; Swartz RJ; Eddings T; Matin SF; Swanson D; Wood CG; Pisters LL; Babaian RJ; Troncoso P; Pettaway CA
BJU Int; 2007 Jul; 100(1):63-9. PubMed ID: 17552954
[TBL] [Abstract][Full Text] [Related]
14. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
[TBL] [Abstract][Full Text] [Related]
15. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
Cheung R; Kamat AM; de Crevoisier R; Allen PK; Lee AK; Tucker SL; Pisters L; Babaian RJ; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):134-40. PubMed ID: 16111581
[TBL] [Abstract][Full Text] [Related]
16. [Anemia in patients on combined androgen block therapy for prostate cancer].
Hua LX; Wu HF; Sui YG; Cheng SG; Xu ZQ; Zhang W
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):496-7. PubMed ID: 14575579
[TBL] [Abstract][Full Text] [Related]
17. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
20. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
